Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast in moderate to severe psoriasis vulgaris
NCT02888236Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orismilast in Psoriasis vulgaris (PV), sponsored by LEO Pharma. Started Sep 2016; status: completed.
02
Drugs
orismilast
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02888236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888236.